Literature DB >> 1998868

Proliferation characteristics of human colorectal carcinomas measured in vivo.

D A Rew1, G D Wilson, I Taylor, P C Weaver.   

Abstract

The cell proliferation kinetics of 100 human colonic and rectal adenocarcinomas have been studied in vivo by bromodeoxyuridine infusion and multiparameter flow cytometry. A total of 97 patients, three with synchronous tumours, consented to receive a single bolus dose of 250 mg between 2.4 and 16 h before curative or palliative surgery. By this method, the ploidy pattern, the total and aneuploid labelling indices (LI), the S phase duration (Ts) and the potential doubling time (Tpot) can be estimated. Of the tumours 48 were diploid and 52 were aneuploid. The mean and median total LI of 100 tumours were 9.0 per cent (range 0.7-22.2 per cent). The mean aneuploid LI was 12.1 per cent (median 12.0 per cent, range 2.0-25.5 per cent), and was significantly higher than the total LI (P = 0.01). The labelling index alone is not a sufficient indicator of proliferation, because the Ts also varies within and between tumours. The intertumour range of the Ts varied from 4.0 to 28.6 h. The mean was 14.1 h and the median was 13.1 h. The mean Tpot was 5.9 days (median 3.9 days) with a range of 1.7-21.4 days. No correlation was found between any kinetic parameters and the Dukes' classification or histological classification. The correlation between proliferation and prognosis will be established in due course.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1998868     DOI: 10.1002/bjs.1800780120

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  21 in total

Review 1.  General surgery.

Authors:  I Taylor
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

Review 2.  Surgical excision alone is adequate treatment for primary colorectal cancer.

Authors:  R Hind; D R Rew; C D Johnson
Journal:  Ann R Coll Surg Engl       Date:  1992-01       Impact factor: 1.891

3.  Cell proliferation, tumour growth and clinical outcome: gains and losses in intestinal cancer.

Authors:  D A Rew
Journal:  Ann R Coll Surg Engl       Date:  1993-11       Impact factor: 1.891

4.  Flow cytometric analysis of multidrug-resistance-associated antigen (P-glycoprotein) and DNA ploidy in human colon cancer.

Authors:  M Danova; M Giordano; E Erba; S Palmeri; V Candiloro; A Riccardi; G Ucci; G Mazzini; M D'Incalci; E Ascari
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

5.  Tumor growth rate determines the timing of optimal chronomodulated treatment schedules.

Authors:  Samuel Bernard; Branka Cajavec Bernard; Francis Lévi; Hanspeter Herzel
Journal:  PLoS Comput Biol       Date:  2010-03-19       Impact factor: 4.475

6.  Potential tumour doubling time: determination of Tpot for various canine and feline tumours.

Authors:  U Schwyn; N E Crompton; H Blattmann; B Hauser; B Klink; A Parvis; D Ruslander; B Kaser-Hotz
Journal:  Vet Res Commun       Date:  1998-06       Impact factor: 2.459

Review 7.  Cell and molecular mechanisms of pathogenesis and treatment of cancer.

Authors:  D A Rew
Journal:  Postgrad Med J       Date:  1998-02       Impact factor: 2.401

8.  Comparative lesion sequencing provides insights into tumor evolution.

Authors:  Siân Jones; Wei-Dong Chen; Giovanni Parmigiani; Frank Diehl; Niko Beerenwinkel; Tibor Antal; Arne Traulsen; Martin A Nowak; Christopher Siegel; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Joseph Willis; Sanford D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-12       Impact factor: 11.205

9.  Proliferation in human gastrointestinal epithelium using bromodeoxyuridine in vivo: data for different sites, proximity to a tumour, and polyposis coli.

Authors:  C S Potten; M Kellett; D A Rew; S A Roberts
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

10.  Single-molecule genomic data delineate patient-specific tumor profiles and cancer stem cell organization.

Authors:  Andrea Sottoriva; Inmaculada Spiteri; Darryl Shibata; Christina Curtis; Simon Tavaré
Journal:  Cancer Res       Date:  2012-10-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.